338 related articles for article (PubMed ID: 32234375)
1. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
2. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
3. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
4. NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Zhao X; Jiang L; Hu D; Tang Y; Zhao G; Du X; Luo S; Tang W
Exp Cell Res; 2021 Jun; 403(2):112614. PubMed ID: 33905671
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
[TBL] [Abstract][Full Text] [Related]
6. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
Hu F; Zhao Y; Yu Y; Fang JM; Cui R; Liu ZQ; Guo XL; Xu Q
Cancer Lett; 2018 Mar; 416():24-30. PubMed ID: 29246644
[TBL] [Abstract][Full Text] [Related]
8. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Wang Q; He WY; Zeng YZ; Hossain A; Gou X
Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells.
Liu MN; Liu AY; Du YJ; Pei FH; Wang XH; Chen J; Liu D; Liu BR
Mol Med Rep; 2015 Jul; 12(1):1189-96. PubMed ID: 25777765
[TBL] [Abstract][Full Text] [Related]
11. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
12. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
[TBL] [Abstract][Full Text] [Related]
13. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
15. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Seo HK; Lee SJ; Kwon WA; Jeong KC
Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
18. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
[TBL] [Abstract][Full Text] [Related]
19. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
20. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
